Company intelligence / Profile preview

Sugen Inc.

South San Francisco, California, United Statessugenlife.com ↗

Ownership: Private
Development stage: Commercial

Overview

Sugen was a trailblazer in developing small-molecule tyrosine kinase inhibitors for cancer therapy but did not bring an FDA-approved drug to market before its acquisition[6]. Its research laid the groundwork for later successful drugs in this class[6].

Therapeutic areas: Oncology
Modalities: Small molecules (notably tyrosine kinase inhibitors)
Industry: Biotech

Drug pipeline

4 assets

SU11752

Preclinical

Indications: Neoplasms

3 more assets in the full pipeline.

Request access →

Partnerships

AstraZeneca held a significant stake pre-acquisition[1]

Beyond the preview

Go deeper on Sugen Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sugen Inc..

Explore the full profile